December 17, 2003

Skinvisible Receives Largest Single Order for Antimicrobial Hand Sanitizer In The Battle Against the Flu Virus

LAS VEGAS, Dec 17, 2003 /PRNewswire-FirstCall via Comtex/ --

Skinvisible, Inc. (OTC Bulletin Board: SKVI) (Website: www.skinvisible.com ) through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc. announces that further to its Press Release of December 15, 2003 (http://www.skinvisible.com/news/press.html ) on its patented Antimicrobial Hand Sanitizer that it has received a purchase order for 1,000 cases of the product.

The order to be shipped by month end is for delivery to Dermal Defense's (www.dermaldefense.com ) exclusive distributor Galls, Inc. 'Americas Premier Authority in Public Safety Equipment'. To order go to www.galls.com keyword search dermal defense or telephone toll free at 1-800-477-7766. 'We see Dermal Defense as being part of everyone's daily hand hygiene,'says James Graves, President of Dermal Defense. 'Our Hand Sanitizer offers everybody a chance to protect themselves, not only during the flu season but all year long'.

Headquartered in Las Vegas, Nevada, Skinvisible, Inc. is focused on the development of innovative topical polymer-based delivery systems and related technologies incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymers into stable water emulsions. Skinvisible's primary marketing and sales objectives are to license its technologies and/or sell its delivery systems to provide enhanced product performance for established brand manufacturers and providers of prescription, over-the-counter, cosmetic, and skincare products. In addition Skinvisible formulates and manufactures products for private label customers.

This press release contains 'forward looking'statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports that will be on file with the US Securities and Exchange Commission (including but not limited to the report on Form 10-QSB for the quarter ending September 30, 2003).

For Corp. Info. Contact: T. Howlett - Skinvisible, Inc. - Ph. (702) 433- 7154 / Fax (702) 433-7192 / Email: terry@skinvisible.com For Media Info. Contact: Tommi Hanley - Thompson Lloyd Communications- Ph. (250) 860- 9959 / Email: tommi.tlc@shaw.ca

Press Release Index

New Press Release Alerts:

If you are interested in receiving corporate and new product development news from Skinvisible, simply enter your email address below.